Posted by Michael Wonder on 28 Jun 2026
Gazyva (obinutuzumab) receives positive reimbursement recommendation from the Institut national d'excellence en santé et en services sociaux (INESSS) for persons with active lupus nephritis
25 June 2026 - Roche Canada is pleased to share that on 3 June 2026, the Institut national d'excellence en santé et en services sociaux (INESSS) recommended Gazyva (obinutuzumab) for public reimbursement in Quebec.
This recommendation is for the treatment of persons with active lupus nephritis who are receiving standard therapy.
This positive recommendation expands the pathway to patient access, following Canada's Drug Agency's positive recommendation on 6 May 2026 and Health Canada's authorisation in January 2026.
